Publications by authors named "A Budaj"
De-escalation of dual antiplatelet (DAPT) intensity may be considered in patients with high risk of bleeding after acute coronary syndrome. Some high risk patients after de-escalation may require antithrombotic therapy prolonged over 12 months. With the current guideline recommended strategies, there are some doubts and uncertainties with respect to the transition period.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the relationship between triglyceride levels and the cardiovascular benefits of alirocumab compared to placebo in patients with recent acute coronary syndrome (ACS) who are on statin therapy.
- Results showed that higher baseline triglyceride levels were linked to an increased risk of major adverse cardiovascular events (MACE), whereas alirocumab significantly lowered LDL cholesterol and reduced MACE risk.
- While alirocumab led to a notable decrease in triglycerides, the reduction did not correlate with a lower risk of MACE, suggesting baseline triglyceride levels are more important for cardiovascular risk than reductions achieved through treatment.
Background: The optimal antithrombotic regimen for patients with atrial fibrillation (AF) who had an acute coronary syndrome (ACS) or have undergone percutaneous coronary intervention (PCI) is not known.
Objectives: The authors sought to determine which antithrombotic regimen best balances safety and efficacy.
Methods: AUGUSTUS, a multicenter 2 × 2 factorial design randomized trial compared apixaban with vitamin K antagonist (VKA) and aspirin with placebo in patients with AF with recent ACS and/or PCI treated with a P2Y inhibitor.